Compare Amylx Pharmaceuticals Inc (AMLX) vs Vanguard S&P 500 Growth Index Fund ETF (VOOG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Vanguard S&P 500 Growth Index Fund ETF — how do they compare? Amylx Pharmaceuticals Inc trades at $24.09 (market cap $2.64B), while Vanguard S&P 500 Growth Index Fund ETF trades at $85.05. Which is the better fit depends on your goals.
| AMLX | VOOG | |
|---|---|---|
Market Cap | $2.64B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $24.19 | $85.42 |
52-Week Low | $7.82 | $65.32 |
Enterprise Value | $2.39B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.66, up 4.37% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$144.74M in 2025, with negative ROE and ROA, while Q2 2026 EPS missed expectations. Key catalysts include the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, as highlighted in recent earnings calls and news.
Analyst consensus is strongly bullish with a $30.00 price target and 91% buy ratings, driven by pipeline potential. However, high cash burn, ongoing losses, and reliance on clinical trial success pose significant risks. The stock offers speculative upside if trials succeed but faces downside from operational challenges and market volatility.
VOOG trades at $85.18, down slightly by 0.02% today. Technical indicators show a bullish trend with moving averages supporting upside momentum, though the relative strength index suggests potential overbought conditions near-term. Recent news highlights institutional accumulation, including Apella Capital increasing holdings by 463.2% as of August 2026, and the ETF hitting a new 52-week high, reflecting strong investor interest in large-cap growth exposure.
The outlook remains positive given the ETF's low expense ratio of 0.07% and focus on S&P 500 growth stocks, but risks include high concentration in technology sectors and sensitivity to market volatility. Continued institutional inflows and bullish technical signals support further gains, though overbought levels warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Vanguard S&P 500 Growth Index Fund ETF
VOOG is an index-based ETF that tracks the S&P 500 Growth Index, composed of the growth-oriented companies within the S&P 500. It selects constituents based on three key metrics—sales growth, the ratio of earnings change to price, and momentum—offering a highly liquid and low-cost way to capture the high-performing 'growth slice' of the broader U.S. large-cap market.
Read more on VOOG →
